Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
'Tangled' live-action movie casts Teagan Croft and Milo Manheim as Rapunzel and Flynn - 2Picking the Right Doctor prescribed Medication Inclusion in Senior Protection.
- 3What are parents to do as doctors clash with Trump administration over vaccines?
- 4Smuggler who called migrants 'chickens' jailed
- 5Independence from the rat race: How to Save and Contribute Shrewdly
- Mom warns of Christmas gift hazard as daughter recovers in hospital
- 6 Travel Services for Colorful Get-aways: Pick Your Fantasy Escape
- See as Your #1: These Low-Sugar Food sources You Ought to Attempt
- The Most Encouraging New companies to Look Out For
- I spent the last year transforming my life. Becoming a Rockette for a day made me confront a fear I couldn't shake.
- Solar storms have influenced our history – an environmental historian explains how they could also threaten our future
- Fisherman Attacked by Great White Shark Says ‘My Left Foot Was in His Mouth’
- Building an Individual Brand: Illustrations from Forces to be reckoned with
- Audits of the Top Science fiction Movies This Year
